A Study of VRT106, Combined With Camrelizumab, and Apatinib for Advanced HCC

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2026
This is an open-label phase II/III clinical trial enrolling patients with advanced HCC who have failed prior ICIs. The phase II portion consists of a part A dose-escalation stage and a part B dose-expansion stage. The phase III study will be initiated following discussions with National Medical Products Administration (NMPA) regarding the phase III protocol, based on accumulated data from phase II including safety, efficacy, pharmacokinetics (PK), and pharmacodynamics (PD).
Epistemonikos ID: 93d3dc539e030c4cef4c918464e083a3b309ecf2
First added on: May 15, 2026